Skip to content
WeighLab

Evidence review

GLP-1 Drugs List (2026): Every Approved GLP-1 for Weight Loss and Diabetes, With Doses and Prices

The short answer

FDA-approved GLP-1 drugs in 2026 include semaglutide (Ozempic, Rybelsus, and the Wegovy shot and pill), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda and generics), dulaglutide (Trulicity) and orforglipron (Foundayo). Only Wegovy, Zepbound, Saxenda and Foundayo are approved for weight loss. Tirzepatide produced more weight loss than semaglutide head to head.

By The WeighLab Bench, Tools & Data Desk
Section index07

"GLP-1" covers a family of drugs that copy or mimic a gut hormone called glucagon-like peptide-1. They lower blood sugar and appetite, and several are approved for weight loss. Some are weekly shots, some are daily shots, and a few are now pills. Below is every GLP-1 the FDA has approved, which ones are for weight loss, how they compare, and what they cost. For how the hormone works, see how a GLP-1 works.

PartnerGrade A

CoreAge Rx

$99/mo sema · $149/mo tirz

Visit CoreAge Rx
Semaglutide
$99/mo
Tirzepatide
$149/mo
Coverage
All 50 states
Brand-name
Compounded only
Modeled / yr
$1,188

CoreAge Rx charges one flat price at every dose, $99 a month for semaglutide and $149 for tirzepatide, with no membership fee.

Read the full CoreAge Rx review →

Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never moves the Index. See our disclosure.

Partner

Bodybuilding Health+

74/100
Semaglutide
$179/moMonth-to-month; $159.33 on three months, $158 on six and $141.50 on twelve
Tirzepatide
$209/moMonth-to-month; $179 on three months, $174.67 on six and $187.33 on twelve
Visit Bodybuilding Health+

Which GLP-1 drugs are FDA-approved?

This table lists every approved GLP-1 product sold under a brand name, plus generic liraglutide. "Year" is the first FDA approval of that application.

Drug (molecule)BrandForm and frequencyApproved forYear
SemaglutideOzempicInjection, weeklyType 2 diabetes; heart and kidney risk in diabetes2017
SemaglutideRybelsus; Ozempic tabletsTablet, dailyType 2 diabetes; heart risk in diabetes2019
SemaglutideWegovyInjection, weeklyWeight loss (adults, teens 12+); heart risk; MASH liver disease2021
SemaglutideWegovy pillTablet, dailyWeight loss and heart risk (adults)2025
Tirzepatide (GLP-1 + GIP)MounjaroInjection, weeklyType 2 diabetes (age 10+); heart risk in diabetes2022
Tirzepatide (GLP-1 + GIP)ZepboundInjection, weeklyWeight loss; sleep apnea with obesity2023
LiraglutideVictozaInjection, dailyType 2 diabetes (age 10+); heart risk in diabetes2010
LiraglutideSaxendaInjection, dailyWeight loss (adults, teens 12+)2014
LiraglutideGeneric liraglutideInjection, dailySame as the brand it copies2024
DulaglutideTrulicityInjection, weeklyType 2 diabetes (age 10+); heart risk in diabetes2014
OrforglipronFoundayoTablet, dailyWeight loss (adults)2026

Sources: Drugs@FDA for each application1234567891011 and each drug's prescribing information121314151617181920.

Two older exenatide products, Byetta (2005, twice daily) and Bydureon (2012, weekly), are listed in Drugs@FDA as discontinued2122. Tirzepatide is technically a dual agonist: it acts on the GIP receptor as well as GLP-1. It's included because it's prescribed and compared as part of the same class. Orforglipron is the odd one out in a different way: it's a small molecule, not a peptide.

Which are approved for weight loss, and which only for diabetes?

Four brands carry a weight-loss approval: Wegovy (shot and pill), Zepbound, Saxenda and Foundayo14161820. All four are approved for adults with obesity, or with overweight plus at least one weight-related condition. Wegovy injection and Saxenda are also approved for teens 12 and older with obesity.

Ozempic, Rybelsus, the Ozempic tablets, Mounjaro, Victoza and Trulicity are approved for type 2 diabetes, not for weight loss. Doctors sometimes prescribe them off-label for weight, but insurers often won't cover that. Each diabetes brand has a weight-loss twin with the same molecule: Ozempic and Wegovy, Mounjaro and Zepbound, Victoza and Saxenda. See Ozempic vs Wegovy, Mounjaro vs Zepbound and Saxenda vs Wegovy.

Which GLP-1 causes the most weight loss?

Tirzepatide, on current evidence. In SURMOUNT-5, the one head-to-head weight-loss trial, people without diabetes lost an average of 20.2% of their body weight on tirzepatide and 13.7% on semaglutide over 72 weeks23.

Drug and doseTrialLengthAverage weight lossPlacebo
Tirzepatide 15 mg weekly (Zepbound)SURMOUNT-172 weeks20.9%3.1%
Tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mgSURMOUNT-572 weeks20.2% vs 13.7%—
Semaglutide 2.4 mg weekly (Wegovy)STEP 168 weeks14.9%2.4%

Sources: SURMOUNT-124, SURMOUNT-523, STEP 125. The pills come in a little lower in their own trials. Wegovy pill vs injection compares the Wegovy pill and Foundayo with the shots. Semaglutide vs tirzepatide and Ozempic vs Mounjaro go deeper on the two leading molecules.

"Best" isn't only about the average. Side effects, how you'd take it, whether insurance covers it and the price all count, and the strongest drug isn't the right one for everybody.

What is the cheapest GLP-1 without insurance?

Among the brands, the pills start cheapest. In October 2026 the Wegovy pill and Foundayo both started at $149 a month and reached $299 at their maintenance doses. The Wegovy pen was $349 a month after a two-fill $199 offer for new patients, and Zepbound vials were $299 to $44926. TrumpRx GLP-1 prices has every dose.

Compounded semaglutide and tirzepatide from telehealth programs usually cost less: a median of $178 and $239 a month respectively, across the programs we track, as of October 2026. They aren't FDA-approved. See cheapest GLP-1 and cheapest GLP-1 over 12 months to compare.

Are there generic GLP-1s?

Yes, one. Generic liraglutide, the drug in Victoza and Saxenda, has been FDA-approved from several manufacturers since December 202411. There is no generic semaglutide or tirzepatide in the U.S. Compounded versions aren't generics: a generic is FDA-approved as equivalent to the brand, and a compounded drug isn't reviewed by the FDA at all. Is compounded semaglutide legit and safe explains the difference.

What's coming next?

Several drugs are in late-stage trials but not approved. The closest is CagriSema, which combines semaglutide with an amylin drug and is under FDA review. CagriSema and the amylin pipeline covers it and its rivals, and retatrutide vs tirzepatide covers Lilly's triple agonist.

What is not a GLP-1?

Phentermine, Contrave, Qsymia and SGLT2 drugs such as Jardiance are sometimes lumped in with GLP-1s, but none of them works on the GLP-1 receptor. Neither do supplements sold as "natural Ozempic." Is phentermine, Contrave or Jardiance a GLP-1? and does berberine work like Ozempic? sort those out. Not medical advice; see our medical disclaimer.

Frequently asked questions

What are the GLP-1 drugs?

The FDA-approved GLP-1 drugs are semaglutide (Ozempic, Rybelsus, Ozempic tablets, Wegovy shot and pill), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda and generic liraglutide), dulaglutide (Trulicity) and orforglipron (Foundayo). Exenatide (Byetta, Bydureon) is listed as discontinued.

Which GLP-1 drugs are approved for weight loss?

Wegovy (injection and pill), Zepbound, Saxenda and Foundayo. Ozempic, Rybelsus, Mounjaro, Victoza and Trulicity are approved for type 2 diabetes, not weight loss.

Which GLP-1 is best for weight loss?

On average, tirzepatide (Zepbound). In the head-to-head SURMOUNT-5 trial, people lost 20.2% of their weight on tirzepatide versus 13.7% on semaglutide over 72 weeks. The right choice also depends on side effects, cost, coverage and whether you prefer a pill or a shot.

Is there a GLP-1 pill?

Yes. The Wegovy pill (oral semaglutide, approved December 2025) and Foundayo (orforglipron, approved April 2026) are daily pills approved for weight loss. Rybelsus and the Ozempic tablets are daily semaglutide pills approved for type 2 diabetes.

Is there a generic GLP-1?

Generic liraglutide, the drug in Victoza and Saxenda, has been FDA-approved since December 2024. There is no generic semaglutide or tirzepatide in the U.S. Compounded versions are not generics and are not FDA-approved.

Is Mounjaro a GLP-1?

Yes, and more. Tirzepatide, the drug in Mounjaro and Zepbound, activates both the GLP-1 and GIP receptors, so it's often called a dual agonist.

References

  1. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 209637, OZEMPIC (semaglutide) injection. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
  2. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 213051, RYBELSUS and OZEMPIC (semaglutide) tablets. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051
  3. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 215256, WEGOVY (semaglutide) injection. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  4. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 218316, WEGOVY (semaglutide) tablets. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
  5. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 215866, MOUNJARO (tirzepatide). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
  6. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 217806, ZEPBOUND (tirzepatide). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
  7. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 022341, VICTOZA (liraglutide). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022341
  8. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 206321, SAXENDA (liraglutide). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206321
  9. U.S. Food and Drug Administration (2026). Drugs@FDA: BLA 125469, TRULICITY (dulaglutide). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
  10. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 220934, FOUNDAYO (orforglipron). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220934
  11. U.S. Food and Drug Administration (2026). Drugs@FDA: ANDA 215503, liraglutide injection (first generic approval, December 2024). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215503
  12. U.S. Food and Drug Administration (2026). OZEMPIC (semaglutide) injection Prescribing Information (SPL June 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  13. U.S. Food and Drug Administration (2026). RYBELSUS and OZEMPIC (semaglutide) tablets Prescribing Information (SPL August 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  14. U.S. Food and Drug Administration (2026). WEGOVY (semaglutide) injection and tablets Prescribing Information (SPL June 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  15. U.S. Food and Drug Administration (2026). MOUNJARO (tirzepatide) injection Prescribing Information (SPL September 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  16. U.S. Food and Drug Administration (2026). ZEPBOUND (tirzepatide) injection Prescribing Information (SPL September 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  17. U.S. Food and Drug Administration (2025). VICTOZA (liraglutide) injection Prescribing Information (SPL November 2025). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
  18. U.S. Food and Drug Administration (2026). SAXENDA (liraglutide) injection Prescribing Information (SPL June 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  19. U.S. Food and Drug Administration (2026). TRULICITY (dulaglutide) injection Prescribing Information (SPL August 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309
  20. U.S. Food and Drug Administration (2026). FOUNDAYO (orforglipron) tablets Prescribing Information (SPL August 2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  21. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 021773, BYETTA (exenatide), marketing status discontinued. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773
  22. U.S. Food and Drug Administration (2026). Drugs@FDA: NDA 022200, BYDUREON (exenatide extended-release), marketing status discontinued. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022200
  23. Aronne LJ, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/40353578/
  24. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  25. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  26. U.S. Department of Health and Human Services (2026). TrumpRx.gov: GLP-1 prices by product and strength (read October 2026). TrumpRx.gov. https://trumprx.gov/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Keep exploring